GemVax & KAEL announced Thursday that its GV1001 has demonstrated radioprotective and anti-fibrotic effects through the suppression of TGF-β (transforming growth factor-beta) signaling.
The Shapiro Family Laboratory of Viral Oncology and Aging Research at the University of California Los Angeles (UCLA) conducted the research. To investigate the effect of GV1001 on cells damaged by radiation damage, the research team irradiated normal human oral keratinocytes and then administered GV1001.
The team confirmed that GV1001 decreased the inhibition of cell proliferation, preserved cell shape, activated recovery of damaged DNA and inhibited the activity of TGF-β signaling substances. To demonstrate the anti-fibrotic effect of GV1001, it also administered the drug to rats induced by skin fibrosis and confirmed that the treatment significantly reduced the thickness of the skin fibrosis lesion.
“Recently, radiation therapy for cancer patients is rapidly increasing, resulting in increased side effects,” the research team said. “This research is meaningful as it proved that GV1001 could be a therapeutic alternative in such situations.”
The team plans to conduct additional research by applying for the U.S. Department of Defense research fund, it added. The results of the study were published in a recent issue of International Journal of Molecular Medicine.
<© Korea Biomedical Review, All rights reserved.>